Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro.
Br J Anaesth
; 132(6): 1204-1210, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594117
3.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Cancer Sci
; 114(12): 4643-4653, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921363
4.
Eosinophil-rich variant of nodal marginal zone lymphoma: a clinicopathological study of 11 cases.
Histopathology
; 83(3): 443-452, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222201
5.
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Jpn J Clin Oncol
; 53(10): 912-921, 2023 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37486002
6.
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
BMC Cancer
; 21(1): 358, 2021 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823836
7.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer
; 28(2): 571-579, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31093770
8.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood
; 130(4): 489-500, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522442
9.
Evaluation of Thrombin and Plasmin Generation Velocity Ratios during Progressive Plasma Dilution.
Anesth Analg
; 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507557
10.
Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Hematol Oncol
; 36(1): 328-335, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28695659
11.
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Ann Hematol
; 97(2): 289-297, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29138885
12.
Effects of Helicobacter pylori eradication on serum lipid levels.
J Clin Biochem Nutr
; 62(3): 264-269, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29892167
13.
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidine.
Ann Hematol
; 101(7): 1587-1589, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35187605
14.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer
; 25(11): 3313-3320, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28551843
15.
Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma.
Rinsho Ketsueki
; 58(5): 427-432, 2017.
Artigo
em Japonês
| MEDLINE | ID: mdl-28592754
16.
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Br J Haematol
; 169(3): 423-34, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25709080
17.
Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.
Haematologica
; 100(1): 87-90, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261092
18.
Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
Transfus Apher Sci
; 52(1): 112-21, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467707
19.
The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients.
Transfusion
; 54(4): 1093-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24147542
20.
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Jpn J Clin Oncol
; 44(5): 435-41, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24664944